PureTech established the underlying programs and platforms that resulted in 27 therapeutic and therapeutic candidates generated from PureTech's R&D engine, including two taken from inception at PureTech to FDA and EU regulatory clearances a third soon filing for FDA approval.
PureTech established the underlying programs and platforms that resulted in 27 therapeutic and therapeutic candidates generated from PureTech's R&D engine, including two taken from inception at PureTech to FDA and EU regulatory clearances a third soon filing for FDA approval.

Wholly Owned Pipeline

Our programs1
Phase 1
Phase 2
Phase 3
Idiopathic pulmonary fibrosis (IPF)



~120K in US

~110K in EU5

Therapeutic candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis (IPF). Also being advanced under the Animal Rule for medical countermeasures; plans underway to study LYT-100 in progressive fibrosing interstitial lung disease (PF-ILDs) as well as other fibrotic conditions where there is human data with pirfenidone suggestive of clinical benefit.

Anti-Galectin-9 mAb
Solid tumors and hematological malignancies


Solid tumors

~82K/year U.S. (Bladder cancer)
~66K/year U.S. (Head and neck cancers)
~20K/year U.S. (AML)

Fully human IgG4 monoclonal antibody, or mAb, designed to inhibit the activity of galectin-9, an immunomodulatory molecule expressed by tumors and immune cells and shown to suppress the immune system from recognizing and destroying cancer cells. We are developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. We are also developing LYT-200 for the treatment of hematological malignancies, such as acute myeloid leukemia (AML).

Oral Allopregnanolone
Anxiety, mood disorders, FXTAS & related indications


Anxiety, mood disorders, FXTAS & related indications

Designed to overcome the poor oral bioavailability of allopregnanolone to advance what we believe could be a best-in-class new medicine for treating anxiety, mood disorders and Fragile X-associated Tremor/ Ataxia Syndrome. Allopregnanolone is a positive allosteric modulator of GABAA receptors that has therapeutic potential across a wide range of neurological conditions, including anxiety and Fragile X-associated Tremor/ Ataxia Syndrome, though its therapeutic application has been limited due to high first pass metabolism. Our Glyph platform reversibly links a drug to a lipid, creating a novel prodrug. We believe this technology has the potential to provide a broadly applicable means of enhancing the bioavailability of certain orally administered drugs that would otherwise be limited by first-pass liver metabolism.

Oral Cannabidiol
Epilepsies & other neurological indications


Epilepsies & other neurological indications

Therapeutic candidate designed to unlock the validated efficacy of cannabidiol (CBD). Derived from the Glyph platform, LYT-310 offers oral dosing and the potential for improved tolerability, which could expand the therapeutic application of CBD across a wider range of age groups and indications, including both rare and more common forms of epilepsy and other neurological indications.

Phase completed
Phase in progress
1 The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that our wholly-owned therapeutic candidates are safe or effective for use by the general public for any indication. On July 23, 2021, Imbrium Therapeutics exercised its option to license LYT-503/IMB-150 pursuant to which it is responsible for all future development activities and funding for LYT-503/IMB-150.

Founded Entities

Investments and Non-Dilutive Funding Raised by Founded Entities Since July 2018

Advancing transformative medicines for people living with psychiatric and neurological conditions

2.8% Equity plus Milestone Payments/ 20% Sublicense Revenue/ Royalties & up to $500M from agreement w/Royalty Pharma3

Pioneering the development of cognitive treatments through game-changing technologies

14.6% Equity

Advancing a novel category of treatments for weight management and gut related chronic diseases

22.8% Equity plus Royalties

Pioneering a new category of oral therapies based on defined bacterial consortia

41% Equity

Engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers

4.0% Equity
PHASE 1/2a

A voice-based artificial intelligence platform to detect changes in health

35.2% Equity

Engineering hydrogels to enable the oral administration of peptide therapeutics (e.g., GLP-1 agonists)

73.8% Equity

Note: This figure represents the stage of development for each Founded Entity’s most advanced therapeutic candidate.PureTech retains control of  Entrega, Inc., and it is consolidated in PureTech’s financial statements. PureTech maintains ownership of equity interests, but does not control, Gelesis Holdings, Inc., Karuna Therapeutics, Inc., Akili, Inc., Sonde Health, Inc. Vor Biopharma Inc., and Vedanta Biosciences, Inc. Relevant ownership interests for non-public Founded Entities, Vedanta, Sonde and Entrega were calculated on a partially diluted basis (as opposed to a voting basis) as of June 30, 2023, including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Karuna, Akili and Vor ownerships were calculated on a beneficial ownership basis in accordance with SEC rules as of July 31, 2023, August 3, 2023 and August 4, 2023, respectively. As of March 1, 2023, the date on which PureTech was deemed to no longer control Vedanta Biosciences, PureTech’s percentage ownership of Vedanta Biosciences was approximately 40.8%. Vedanta’s 2023 $106.5 million financing round was structured as convertible debt. PureTech’s current ownership does not take into account any potential future dilution, if applicable, as a result of conversion of that debt amount. Gelesis ownership represents the percentage of Gelesis’ outstanding common stock held by PureTech as of August 11, 2023. On a beneficial ownership basis (as calculated in accordance with SEC rules), PureTech owns 92.0% of the outstanding share capital of Gelesis as of June 12, 2023. On June 12, 2023, PureTech entered into an Agreement and Plan of Merger to acquire all of the outstanding equity and equity-linked securities of Gelesis and to cause Gelesis to become an indirect wholly owned subsidiary of PureTech upon consummation of the transaction. Please see PureTech’s Schedule 13D filings with respect to Gelesis on file with SEC for additional information. PureTech is also eligible to receive certain payments from Gelesis under its license agreement, including sublicense payments and royalties on sales of certain products, including Plenity. With the exception of Plenity® and EndeavorRx®, candidates are investigational and have not been cleared by the FDA for use in the U.S.
2 Funding figure can include private equity financings, loans and promissory notes, public offerings or grant awards, and gross proceeds from SPAC mergers. Funding figure excludes future milestone considerations received in conjunction with partnerships and collaborations.
3 As of March 22, 2023, PureTech has sold its right to receive a 3% royalty from Karuna to Royalty Pharma on net sales up to $2 billion annually, after which threshold PureTech will receive 67% of the royalty payments and Royalty Pharma will receive 33%. PureTech retains its equity ownership in Karuna. Additionally, under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals and 20% of sublicense income.

Consolidated Cash and cash equivalents

Consolidated Cash and cash equivalents as of June 30, 2023
Operational Runway into Q1 2026

Developing breakthrough medicines at PureTech

Relationships with leading pharma companies or their investment arms

Relationships with leading pharma companies or their investment arms